trending Market Intelligence /marketintelligence/en/news-insights/trending/dgy96s7WowE7oCnW-Mu7KA2 content esgSubNav
In This List

BioTime closes acquisition of Asterias Biotherapeutics

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


BioTime closes acquisition of Asterias Biotherapeutics

Alameda, Calif.-based BioTime Inc. completed its acquisition of biotechnology company Asterias Biotherapeutics Inc.

Under the all-stock deal, Asterias shareholders received 0.71 share of BioTime for each Asterias share held. Asterias owns about 16.2% of the combined company.

Asterias Biotherapeutics has filed for the delisting of its common shares on NYSE American following completion of the deal.

Fremont, Calif.-based Asterias develops cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer.